Frankfurt - Delayed Quote EUR

Diamyd Medical AB (publ) (DMN.F)

0.6740

+0.0180

+(2.74%)

As of 9:16:57 AM GMT+2. Market Open.

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

Diamyd Medical today announced a successful interim analysis (non-futility test) for its ongoing precision medicine Phase 3 DIAGNODE-3 trial. The interim analysis, reviewed by an independent Data Safety Monitoring Board (DSMB), resulted in a favorable recommendation to continue the trial without any modifications.

PR Newswire 8 months ago

DMYD-B.ST
-2.05%
Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd® - for the prevention of Type 1 Diabetes

Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum) to treat Type 1 Diabetes in pediatric patients with Stage 1 or Stage 2 Type 1 Diabetes carrying the genotype HLA DR3-DQ2. Earlier this year, Diamyd® received Fast Track designation for the treatment of individuals with Stage 3 Type 1 Diabetes carrying the HLA DR3-DQ2 genotype. The FDA grants Fast Track designation to facilitate the development and expedite

PR Newswire 9 months ago

DMYD-B.ST
-2.05%

Performance Overview

Return	DMN.F	OMX Stockholm 30 Index (^OMX)
YTD	-53.71%	-3.96%
1-Year	-14.58%	-6.23%
3-Year	-58.15%	+13.83%